Publications of the Division of Health Economics

Journals with external peer review

2019

T. Ran, C.-Y- Cheng, B. Misselwitz, H. Brenner, J. Ubels, M. Schlander:
Cost–effectiveness of colorectal cancer screening strategies: A systematic review.
Clinical Gastroenterology and Hepatology, in press (2019).
DOI: 10.1016/j.cgh.2019.01.014.

M. Wagner, D.Samaha, R.Casciano, M. Brougham, P. Abrishami, C. Petrie, B. Avouac, L. Mantovani, A. Sarría-Santamera, P. Kind, M. Schlander:
Moving towards accountability for reasonableness: A systematic exploration of the features of legitimate healthcare coverage decision-making processes using rare diseases and regenerative therapies as a case study.
International Journal of Health Policy and Management, (2019) 8(7) 424-443.
DOI: 10.15171/ijhpm.2019.24.

R. Schaefer, M. Schlander:
Is the National Institute for Health and Care Excellence (NICE) in England more ´innovation-friendly´ than the Federal Joint Committee (GBA) in Germany?
Expert Review of Pharmacoeconomics & Outcomes Research, (2019) 19(4) 453-462.
DOI: 10.1080/14737167.2019.1559732.

J. J. Caro, J.E. Brazier, J. Karnon, P. Kolominsky-Rabas, A. J. McGuire, E. Nord, M. Schlander:
Determining value in Health Technology Assessment: Stay the course or tack away?
PharmacoEconomics, (2019) 37(3) 293-299.
DOI: 10.1007/s40273-018-0742-2.

J. Richardson, M. Schlander:
Health Technology Assessment (HTA) and economic evaluation: Efficiency or fairness first.
Journal of Market Access & Health Policy, (2019) 7(1) 1-12.
DOI: 10.1080/20016689.2018.1557981.

D. Moro, M. Schlander, H. Telser, O. Sola-Morales, A. Olaye, C. Camp et al.:
Evaluationg discrete choice experiment willingness to pay [DCE-WTP], and relative social willingness to pay [RS-WTP] analysis in a health technology assessment of a treatment for an ultra-rare childhood disease [CLN2].
Expert Review of Pharmacoeconomics & Outcomes Research, under review (2019).

T. Ran, S.B. Eichmüller, P. Schmidt, M. Schlander:
Cost estimation of decentralized T-Cell production in a non-profit setting.
Cancer, under review (2019).

2018

M.-J. Linton, P. M. Mitchell, H. Al-Janabi, M. Schlander, J. Richardson, A. Iezzi, J. Ubels, J. Coast:
Comparing the German translation of the ICECAP-A capability wellbeing measure to the original English version: psychometric properties across healthy samples and seven health condition groups.
Applied Research in Quality of Life, (2018) 1-23.
DOI: 1-23. 10.1007/s11482-018-9681-5.

V. Jantzer, M. Schlander, J. Haffner, P. Parzer, S. Trick, F. Resch, M. Kaess:
The cost incurred by victims of bullying from a societal perspective: Estimates based on a German online survey of adolescents.
European Child and Adolescent Psychiatry, (2019) 28(4) 585-594.
DOI: 10.1007/s00787-018-1224-y.

M. Schlander, C.-Y. Cheng, T. Ran:
The health economics of cancer screening in Germany: Which population-based interventions are cost-effective? [Gesundheitsökonomie der Krebsfrüherkennung in Deutschland: Welche Interventionen sind kosteneffektiv bei bevölkerungsweiter Umsetzung?]
Bundesgesundheitsblatt, (2018) 61(12) 1559-1568.
DOI: 10.1007/s00103-018-2839-3.

J. Espin, M. Schlander, B. Godman, P. Anderson, J. Mestre-Ferrandiz, I. Borget, A. Hutchings, S. Flostrand, A. Paranby, C. Jommi:
Projecting pharmaceutical expenditure in EU5 to 2021: Adjusting for the impact of discounts and rebates.
Applied Health Economics and Health Policy, (2018) 16(6) 803-817.
DOI: 10.1007/s40258-018-0419-1.

K. Hernandez-Villafuerte, A. Fischer, N. R. Latimer:
Challenges and methodologies in using progression free survival as a surrogate for overall survival in oncology.
International Journal of Technology Assessment in Health Care, (2018) 34(3) 300-316.
DOI: 10.1017/S0266462318000338.

2017

M. Schlander, C.-M. Dintsios, A. Gandjour:
Budgetary impact and cost drivers of drugs for rare and ultrarare diseases.
Value in Health, (2017) 21(5) 525-531.
DOI: 10.1016/j.jval.2017.10.015.

G. Steigner, C. Doarn, M. Schütte, D. Matusiewicz, C. Thielscher:
Health applications for corporate health management.
Telemedicine and E-Health, (2017) 23(5) 448-452.
DOI: 10.1089/tmj.2016.0162.

L. Annemans, S. Aymé, Y. Le Cam, K. Facey, P. Gunther, E. Nicod, M. Reni, J.-L. Roux, M. Schlander, D. Taylor, C. Tomino, J, Torrent-Farnell, S. Upadhyaya, A. Hutchings, L. Le Dez:
Recommendations from the European working group for value assessment and funding processes in rare diseases.
Orphanet Journal of Rare Diseases, (2017) 12 (50) 1-15.
DOI: 10.1186/s13023-017-0601-9.

K. Hernandez-Villafuerte, J. Sussex, E. Robin, S. Guthrie, S. Wooding:
Economies of scale and scope in publicly funded biomedical and health research: Evidence from the literature.
Health Research Policy and Systems, (2017) 15(3).
DOI 10.1186/s12961-016-0167-3.

Non-refereed publications

2018

M. Schlander:
Opportunities for cooperation between the Division of Health Economics at DKFZ & Clinical Researchers (at U of Heidelberg, NCT, DKTK).
Heidelberg, April 17, 2019.

K. Hernandez-Villafuerte, B. Zamora, Y. Feng, D. Parkin, N. Devlin, A. Towse:
Exploring variations in the opportunity cost cost-effectiveness threshold by clinical area: Results from a feasibility study in England.
Office of Health Economics, (2018) OHE Research Paper 19/3.

M. Schlander, K. Hernandez-Villafuerte, C. Thielscher:
Cost of cancer in Germany [Kosten der Onkologie in Deutschland].
Forum, (2018) 33(5) 330-337.

K. Hernandez-Villafuerte, B. Zamora, A. Towse:
Issues surrounding the estimation of the opportunity cost of adopting a new health care technology: Areas for Further Research.
Office of Health Economics, (2018) OHE Research Paper 18/7.

A. Towse, K. Hernandez-Villafuerte, B. Shaw:
A critique of the paper “The estimated costs of production and potential prices for the World Health Organization Essential Medicines List”.
Office of Health Economics, (2018) OHE Consulting Report.

M. Schlander:
Was ist uns die Krebsversorgung wert?
360° Onkologie Krebs und Politik, (2018) 2(5) 4.

M. Schlander:
Das Schreckgespenst der Kostenexplosion ist nicht gut begründet.
Frankfurter Allgemeine Zeitung, April 13, 2018, V2.

H. Telser, B. Fischer, M. Schlander:
Knappe Ressourcen und unbegrenzte Wünsche.
Im Dialog - CSS Journal 1, (2018) 4-6.

M.Schlander, B. Fischer, H.Telser:
Mithilfe der Wissenschaft die Kosten bremsen.
Im Dialog - CSS Journal 1, (2018) 8-9.

2017

T. Penzel, I. Flindell, R. Höger, U. Krämer, M. Schlander, J. Vogt, H.-E. Wichmann:
Evaluierung der Forschung zur Wirkung von Fluglärm auf den Menschen.
Interdisziplinäres Schlafzentrum Charité, Universitätsmedizin Berlin (2017).

C. Thielscher:
Was kann die Gesundheitswirtschaft von der Medizin lernen?
D. Matusiewicz, M. Muhrer-Schwaiger (eds.):
Neuvermessung der Gesundheitswirtschaft (2017) Springer, 253-268.

M. Schlander, O. Schwarz, G.-E. Trott:
Unanswered questions: ADHD in Germany: trends in diagnosis and pharmacotherapy [ADHS in Deutschland: Trends in Diagnose und medikamentöser Therapie].
Deutsches Ärzteblatt International (2017) 114(25): 428-429. DOI: 10.3238/arztebl.2017.0428a

M. Schlander:
Woran bemisst sich Effizienz im Gesundheitswesen? Zur Klärung fachwissenschaftlicher Begriffe und Kriterien.
Amos International, (2017) 11(1) 22-31.

M. Schlander:
Gescheiterte Börsenfusion – oder "Whatever it takes".
Frankfurter Allgemeine Zeitung, April 11, 2017: 6.

to top